Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin57.2%+1.8pp55.4%+0.9pp54.5%+0.6pp53.9%0.0pp53.9%-1.2pp
Operating margin-70.1%+1.4pp-71.5%+5.9pp-77.4%+2.7pp-80.1%-2.2pp-78%-8.5pp
Net margin-60.3%+12.7pp-73%+14.9pp-87.9%+6.1pp-94%+7.6pp-101.6%-17.5pp
EBITDA margin-68.4%+1.5pp-69.9%+6.1pp-76%+2.6pp-78.6%-2.3pp-76.3%-8.6pp
Free cash flow margin-55.4%+0.6pp-56.1%+12.3pp-68.3%+11.2pp-79.5%+5.6pp-85.1%-5.8pp
Efficiency
Inventory turnover2.4×-0.2×2.6×-0.8×3.3×-0.1×3.4×-0.2×3.5×-0.5×
Liquidity
Current ratio10.7×+2.0×8.7×-2.0×10.6×
Quick ratio9.7×+1.7×-1.9×9.8×
Cash ratio1.3×+0.3×-0.5×1.5×
Leverage
Debt-to-equity0.0×
Debt-to-assets0.0×0.0×
Per Share
Book value per share$6.10-14.0%$7.10+5.0%$6.76-2.8%$6.95-31.9%$10.22+126%
Valuation
Market capitalization$708.98M-8.6%
Enterprise value$685.68M
Price / sales6.4×
Price / book2.6×
EV / sales6.2×
Free cash flow yield-8.6%
Earnings yield-9.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Beta Bionics, Inc. Common Stock's profit margins?
Beta Bionics, Inc. Common Stock (BBNX) runs a 57.2% gross margin and a -70.1% operating margin, with a -60.3% net margin.
Where do Beta Bionics, Inc. Common Stock's ratios come from?
Every ratio is computed from Beta Bionics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.